Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2
Dwight Hall Owen, Navneet Singh, Nofisat Ismaila et al. · Journal of Clinical Oncology · 2022
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See Appendix 1 (online only) for disclaimers and other important information. Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline .
Cited by 32 works. doi:10.1200/jco.22.02124 Open-access PDF
Authors
- Dwight Hall Owen
- Navneet Singh
- Nofisat Ismaila
- Elizabeth M. Blanchard
- Paul Celano
- Narjust Florez
- Dharamvir Jain
- Natasha B. Leighl
- Hirva Mansurali Mamdani
- Gregory A. Masters
- Pamela R. Moffitt
- Jarushka Naidoo
- Tanyanika Phillips
- Gregory J. Riely
- Andrew George Robinson
- Erin Lynn Schenk
- Bryan James Schneider
- Lecia Van Dam Sequist
- David Robert Spigel
- Ishmael A. Jaiyesimi
References
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
- LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
- Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
- Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
- A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer
- LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial